ADMA BIOLOGICS INC (ADMA) Stock News
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA Latest News, Press Relases and Analysis
Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA).
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $21.31, signifying a +0.38% move from its prior day's close.
UnitedHealth Loses $120 Billion in Value on Stock's Worst Day Since 1998
UnitedHealth Group stock had one of its worst days ever on Thursday after the healthcare giant unexpectedly cut its profit forecast for the year.
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
ADMA Biologics (ADMA): Among Louis Navellier’s New Stock Picks
We recently published a list of Louis Navellier’s 10 New Stock Picks. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other Louis Navellier’s new stock picks. Navellier & Associates is an independent money management firm founded in 1987 by renowned growth analyst Louis Navellier. Based in […]
Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday?
We recently published a list of 10 Firms End Stronger on Tuesday. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other firms that end stronger on Tuesday. A muted trading persisted on the stock market on Tuesday, with major indices ending in the red, recording minimal […]
Prediction: The Dow Jones Industrial Average Will Hit 1 Million Within 50 Years. Here's Why.
With the Dow Jones Industrial Average (DJINDICES: ^DJI) sitting around 40,000, it may seem like a big stretch to expect it to reach 1 million at any point. After all, in the year 1900, the Dow was at 66. It likely won't take a century for the Dow to reach the 1 million milestone.
Janover Doubles Solana Holdings to $21M, Sees 1,700% Stock Surge After Crypto Pivot
Janover, a real estate-focused fintech company, has ramped up its investments in Solana (SOL), now holding a total of 163,651 tokens, valued at approximately $21.2 million.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated...
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know
The latest trading day saw Adma Biologics (ADMA) settling at $20.25, representing a -0.15% change from its previous close.
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation...
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end...
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET...
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
Pharma Stock Poised to Bounce Off Support
ADMA Biologics stock has pulled back to its bullish 200-day moving average
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
ADMA Biologics Announces Preliminary Full Year 2024 Revenue and Provides Business Update
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
SpringWorks Therapeutics Stock Gets A RS Rating Lift
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end...
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA’s Total Debt to $75 Million, a 29% Reduction ...